Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 341-350

  Kim, Garam ^a   Khanal, Prem ^a   Lim, Sung Chul ^b   Yun, Hyo Jeong ^a   Ahn, Sang Gun ^a   Ki, Sung Hwan ^a   Choi, Hong Seok ^a  

^a Chosun University   (South Korea)

^b Chosun University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C FOS; PROTEIN C JUN; SMALL INTERFERING RNA; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL STRAIN MCF 7; CHORIOALLANTOIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR PROGRESSION LOCUS 2; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHICKENS; CHORIOALLANTOIC MEMBRANE; EPIDERMIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-17; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, INTERLEUKIN-17; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 84873529688     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs342     Document Type: Article

References (50)

1. Wang,L. et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med., 206, 1457-1464.
2. Xiao,M. et al. (2009) IFNgamma promotes papilloma development by upregulating Th17-associated inflammation. Cancer Res., 69, 2010-2017.
3. Yao,Z. et al. (1995) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity, 3, 811-821.
4. Fossiez,F. et al. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med., 183, 2593-2603.
5. Matusevicius,D. et al. (1999) Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler., 5, 101-104.
6. Jovanovic,D.V. et al. (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol., 160, 3513-3521.
7. Teunissen,M.B. et al. (1998) Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol., 111, 645-649.
8. Chabaud,M. et al. (1998) Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol., 161, 409-414.
9. Attur,M.G. et al. (1997) Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum., 40, 1050-1053.
10. Shalom-Barak,T. et al. (1998) Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J. Biol. Chem., 273, 27467-27473.
11. Awane,M. et al. (1999) NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J. Immunol., 162, 5337-5344.
12. Wu,S. et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med., 15, 1016-1022.
13. Tartour,E. et al. (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res., 59, 3698-3704.
14. Higashi,T. et al. (1990) Hamster cell line suitable for transfection assay of transforming genes. Proc. Natl. Acad. Sci. U.S.A., 87, 2409-2413.
15. Erny,K.M. et al. (1996) Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene, 13, 2015-2020.
16. Ceci,J.D. et al. (1997) Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev., 11, 688-700.
17. Salmeron,A. et al. (1996) Activation of MEK-1 and SEK-1 by Tpl-2 protooncoprotein, a novel MAP kinase kinase kinase. EMBO J., 15, 817-826.
18. Das,S. et al. (2005) Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J. Biol. Chem., 280, 23748-23757.
19. Christoforidou,A.V. et al. (2004) Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol. Cancer, 3, 34.
20. Clark,A.M. et al. (2004) Mutational activation of the MAP3K8 protooncogene in lung cancer. Genes. Chromosomes Cancer, 41, 99-108.
21. Sourvinos,G. et al. (1999) Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene, 18, 4968-4973.
22. Tsatsanis,C. et al. (1998) The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and induces interleukin 2 expression in T cell lines. Proc. Natl. Acad. Sci. U.S.A., 95, 3827-3832.
23. Khanal,P. et al. (2009) Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF. Carcinogenesis, 30, 682-689.
24. Stafford,M.J. et al. (2006) Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett., 580, 4010-4014.
25. Sugimoto,K. et al. (2004) A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. J. Clin. Invest., 114, 857-866.
26. Dong,Z. et al. (2002) Harvesting cells under anchorage-independent cell transformation conditions for biochemical analyses. Sci. STKE, 2002, pl7.
27. Eferl,R. et al. (2003) AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer, 3, 859-868.
28. Karin,M. (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem., 270, 16483-16486.
29. Su,X. et al. (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol., 184, 1630-1641.
30. Aggarwal,S. et al. (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem., 278, 1910-1914.
31. Yu,H. et al. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 9, 798-809.
32. Qian,L. et al. (2006) A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells. Biochem. Biophys. Res. Commun., 345, 660-668.
33. Wang,L. et al. (2012) Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS ONE, 7, e34400.
34. Fujino,S. et al. (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 52, 65-70.
35. Tzartos,J.S. et al. (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol., 172, 146-155.
36. Chabaud,M. et al. (2000) Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine, 12, 1092-1099.
37. Kato,T. et al. (2001) Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun., 282, 735-738.
38. Hirahara,N. et al. (2001) Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology, 61, 79-89.
39. Dumitru,C.D. et al. (2000) TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell, 103, 1071-1083.
40. Kontoyiannis,D. et al. (2002) Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factorinduced Crohn's-like inflammatory bowel disease. J. Exp. Med., 196, 1563-1574.
41. Ohara,R. et al. (1995) Identification of the cells expressing cot proto-oncogene mRNA. J. Cell. Sci., 108 (Pt 1), 97-103.
42. Choi,H.S. et al. (2008) Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity. FASEB J., 22, 113-126.
43. Iyoda,M. et al. (2010) IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. Am. J. Physiol. Renal Physiol., 298, F779-F787.
44. Karin,M. (1996) The regulation of AP-1 activity by mitogen-activated protein kinases. Philos. Trans. R. Soc. Lond., B, Biol. Sci., 351, 127-134.
45. Khanal,P. et al. (2011) 5'-Nitro-indirubinoxime inhibits epidermal growth factor- and phorbol ester-induced AP-1 activity and cell transformation through inhibition of phosphorylation of Pin1. Mol. Carcinog., 50, 961-971.
46. Gaffen,S.L. (2011) Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol., 23, 613-619.
47. Iwakura,Y. et al. (2006) The IL-23/IL-17 axis in inflammation. J. Clin. Invest., 116, 1218-1222.
48. Xie,Y. et al. (2010) Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest., 28, 598-607.
49. Tong,Z. et al. (2012) A protective role by interleukin-17F in colon tumorigenesis. PLoS ONE, 7, e34959.
50. Wang,L. et al. (2010) IL-17 enhances tumor development in carcinogeninduced skin cancer. Cancer Res., 70, 10112-10120.